PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Current and future biomarkers for pancreatic adenocarcinoma.

Abstract Although pancreatic cancer is only the twelfth most common type of cancer in the world, it features a very unfavorable prognosis. The mortality rate almost equals the incidence rate, corroborating the very poor prognosis of pancreatic cancer. The 5-year survival rate for all stages of pancreatic ductal adenocarcinoma is only 7%. Surgical resection represents the only potentially curative treatment option for pancreatic ductal adenocarcinoma patients but is often not feasible due to the advanced stage of the disease upon diagnosis. For advanced disease, palliative chemotherapy is the treatment of choice although the regimens available to date are untargeted and have extensive side-effect profiles, making them unsuitable for patients with a low performance status. For this reason, early detection of pancreatic cancer is essential in order to provide patients with an optimal therapeutic approach. Up to the present day, carbohydrate antigen 19-9 is the only diagnostic marker approved by the U.S. Food and Drug Administration but its diagnostic potential is limited due to its restricted sensitivity and specificity, supporting the urgent need for novel biomarkers. In addition, prognostic and treatment-predictive biomarkers might provide essential information regarding personalized treatment decisions for individual patients. In this article, we aim to review current and future diagnostic, prognostic, and treatment-predictive biomarkers for pancreatic cancer.
PMID
Related Publications

Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.

New biomarkers and targets in pancreatic cancer and their application to treatment.

Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

Prognostic and predictive markers in pancreatic adenocarcinoma.

Authors

Mayor MeshTerms
Keywords

FOLFIRINOX

MicroRNAs

PAM4

gemcitabine

human equilibrative nucleoside transporter 1

macrophage inhibitory cytokine 1

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28618958
OWN - NLM
STAT- MEDLINE
DA  - 20170616
DCOM- 20170705
LR  - 20170705
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Current and future biomarkers for pancreatic adenocarcinoma.
PG  - 1010428317692231
LID - 10.1177/1010428317692231 [doi]
AB  - Although pancreatic cancer is only the twelfth most common type of cancer in the 
      world, it features a very unfavorable prognosis. The mortality rate almost equals
      the incidence rate, corroborating the very poor prognosis of pancreatic cancer.
      The 5-year survival rate for all stages of pancreatic ductal adenocarcinoma is
      only 7%. Surgical resection represents the only potentially curative treatment
      option for pancreatic ductal adenocarcinoma patients but is often not feasible
      due to the advanced stage of the disease upon diagnosis. For advanced disease,
      palliative chemotherapy is the treatment of choice although the regimens
      available to date are untargeted and have extensive side-effect profiles, making 
      them unsuitable for patients with a low performance status. For this reason,
      early detection of pancreatic cancer is essential in order to provide patients
      with an optimal therapeutic approach. Up to the present day, carbohydrate antigen
      19-9 is the only diagnostic marker approved by the U.S. Food and Drug
      Administration but its diagnostic potential is limited due to its restricted
      sensitivity and specificity, supporting the urgent need for novel biomarkers. In 
      addition, prognostic and treatment-predictive biomarkers might provide essential 
      information regarding personalized treatment decisions for individual patients.
      In this article, we aim to review current and future diagnostic, prognostic, and 
      treatment-predictive biomarkers for pancreatic cancer.
FAU - Loosen, Sven H
AU  - Loosen SH
AD  - 1 Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine 
      (Department of Medicine III), Division of GI Oncology, University Hospital RWTH
      Aachen, Aachen, Germany.
FAU - Neumann, Ulf P
AU  - Neumann UP
AD  - 2 Department of Surgery, University Hospital RWTH Aachen, Aachen, Germany.
FAU - Trautwein, Christian
AU  - Trautwein C
AD  - 1 Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine 
      (Department of Medicine III), Division of GI Oncology, University Hospital RWTH
      Aachen, Aachen, Germany.
FAU - Roderburg, Christoph
AU  - Roderburg C
AD  - 1 Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine 
      (Department of Medicine III), Division of GI Oncology, University Hospital RWTH
      Aachen, Aachen, Germany.
FAU - Luedde, Tom
AU  - Luedde T
AD  - 1 Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine 
      (Department of Medicine III), Division of GI Oncology, University Hospital RWTH
      Aachen, Aachen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (Equilibrative Nucleoside Transporter 1)
RN  - 0 (Growth Differentiation Factor 15)
RN  - 0 (PAM4 protein, human)
RN  - 0 (SLC29A1 protein, human)
SB  - IM
MH  - Adenocarcinoma/diagnosis/drug therapy/*genetics/pathology
MH  - Antigens, Neoplasm/genetics
MH  - Biomarkers, Pharmacological
MH  - Biomarkers, Tumor/*genetics
MH  - CA-19-9 Antigen/*genetics
MH  - Equilibrative Nucleoside Transporter 1/genetics
MH  - Growth Differentiation Factor 15/genetics
MH  - Humans
MH  - Pancreatic Neoplasms/diagnosis/drug therapy/*genetics/pathology
MH  - Prognosis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - FOLFIRINOX
OT  - MicroRNAs
OT  - PAM4
OT  - gemcitabine
OT  - human equilibrative nucleoside transporter 1
OT  - macrophage inhibitory cytokine 1
EDAT- 2017/06/18 06:00
MHDA- 2017/07/06 06:00
CRDT- 2017/06/17 06:00
AID - 10.1177/1010428317692231 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317692231. doi: 10.1177/1010428317692231.